Application and insights of targeted next-generation sequencing in a large cohort of 46,XY disorders of sex development in Chinese.
46,XY disorders of sex development
Genetic diagnostic rate
Oligogenic variants
Targeted next generation sequencing
Journal
Biology of sex differences
ISSN: 2042-6410
Titre abrégé: Biol Sex Differ
Pays: England
ID NLM: 101548963
Informations de publication
Date de publication:
16 Sep 2024
16 Sep 2024
Historique:
received:
13
03
2024
accepted:
05
09
2024
medline:
17
9
2024
pubmed:
17
9
2024
entrez:
16
9
2024
Statut:
epublish
Résumé
46,XY disorders of sex development (46,XY DSD) are characterized by incomplete masculinization of genitalia with reduced androgenization. Accurate clinical management remains challenging, especially based solely on physical examination. Targeted next-generation sequencing (NGS) with known pathogenic genes provides a powerful tool for diagnosis efficiency. This study aims to identify the prevalent genetic variants by targeted NGS technology and investigate the diagnostic rate in a large cohort of 46,XY DSD patients, with most of them presenting atypical phenotypes. Two different DSD panels were developed for sequencing purposes, targeting a cohort of 402 patients diagnosed with 46,XY DSD, who were recruited from the Department of Urology at Children's Hospital, Zhejiang University School of Medicine (Hangzhou, China). The detailed clinical characteristics were evaluated, and peripheral blood was collected for targeted panels to find the patients' variants. The clinical significance of these variants was annotated according to American College of Medical Genetics and Genomics (ACMG) guidelines. A total of 108 variants across 42 genes were found in 107 patients, including 46 pathogenic or likely pathogenic variants, with 45.7%(21/46) being novel. Among these genes, SRD5A2, AR, FGFR1, LHCGR, NR5A1, CHD7 were the most frequently observed. Besides, we also detected some uncommon causative genes like SOS1, and GNAS. Oligogenic variants were also identified in 9 patients, including several combinations PROKR2/FGFR1/CYP11B1, PROKR2/ATRX, PROKR2/AR, FGFR1/LHCGR/POR, FGFR1/NR5A1, GATA4/NR5A1, WNT4/AR, MAP3K1/FOXL2, WNT4/AR, and SOS1/FOXL2. The overall genetic diagnostic rate was 11.2%(45/402), with an additional 15.4% (62/402) having variants of uncertain significance. Additionally, trio/duo patients had a higher genetic diagnostic rate (13.4%) compared to singletons (8.6%), with a higher proportion of singletons (15.1%) presenting variants of uncertain significance. In conclusion, targeted gene panels identified pathogenic variants in a Chinese 46,XY DSD cohort, expanding the genetic understanding and providing evidence for known pathogenic genes' involvement. 46,XY disorders of sex development (46,XY DSD) are conditions where individuals don’t fully develop male genitalia due to reduced androgen hormones. Diagnosing these conditions based only on physical exams is difficult. This study used advanced genetic testing called targeted next-generation sequencing (NGS) to identify common genetic variations in a large group of 46,XY DSD patients, many of whom had unusual symptoms. We examined 402 patients with DSD and a 46,XY karyotype, focusing on 142 candidate genes related to sex development. We found genetic variations in 107 patients, including 45 that were likely responsible for their condition. Some of these variations were new discoveries. The most commonly affected genes were SRD5A2, AR, FGFR1, LHCGR, NR5A1, CHD7. We also found that some patients had variations in multiple genes, suggesting complex genetic causes. Overall, we were able to diagnose 11.2% of patients based on our genetic testing, with another15.4% having uncertain results. Patients tested as a trio or duo (with their parents) had a higher diagnosis rate than those tested alone. This study helps expand our understanding of the genetic factors behind 46,XY DSD in the Chinese population.
Autres résumés
Type: plain-language-summary
(eng)
46,XY disorders of sex development (46,XY DSD) are conditions where individuals don’t fully develop male genitalia due to reduced androgen hormones. Diagnosing these conditions based only on physical exams is difficult. This study used advanced genetic testing called targeted next-generation sequencing (NGS) to identify common genetic variations in a large group of 46,XY DSD patients, many of whom had unusual symptoms. We examined 402 patients with DSD and a 46,XY karyotype, focusing on 142 candidate genes related to sex development. We found genetic variations in 107 patients, including 45 that were likely responsible for their condition. Some of these variations were new discoveries. The most commonly affected genes were SRD5A2, AR, FGFR1, LHCGR, NR5A1, CHD7. We also found that some patients had variations in multiple genes, suggesting complex genetic causes. Overall, we were able to diagnose 11.2% of patients based on our genetic testing, with another15.4% having uncertain results. Patients tested as a trio or duo (with their parents) had a higher diagnosis rate than those tested alone. This study helps expand our understanding of the genetic factors behind 46,XY DSD in the Chinese population.
Identifiants
pubmed: 39285472
doi: 10.1186/s13293-024-00648-6
pii: 10.1186/s13293-024-00648-6
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
73Informations de copyright
© 2024. The Author(s).
Références
Hughes IA, Houk C, Ahmed SF, Lee PA, Group LC, Group EC. Consensus statement on management of intersex disorders. Arch Dis Child. 2006;91:7554–63. https://doi.org/10.1136/adc.2006.098319 .
doi: 10.1136/adc.2006.098319
Nordenvall AS, Frisen L, Nordenstrom A, Lichtenstein P, Nordenskjold A. Population based nationwide study of hypospadias in Sweden, 1973 to 2009: incidence and risk factors. J Urol. 2014;191:3:783–9. https://doi.org/10.1016/j.juro.2013.09.058 .
doi: 10.1016/j.juro.2013.09.058
pubmed: 24096117
Wisniewski AB, Batista RL, Costa EMF, Finlayson C, Sircili MHP, Denes FT, et al. Management of 46,XY Differences/Disorders of Sex Development (DSD) throughout life. Endocr Rev. 2019;40:6:1547–72. https://doi.org/10.1210/er.2019-00049 .
doi: 10.1210/er.2019-00049
pubmed: 31365064
Lampalzer U, Briken P, Schweizer K. Psychosocial care and support in the field of intersex/diverse sex development (dsd): counselling experiences, localisation and needed improvements. Int J Impot Res. 2021;33:2228–42. https://doi.org/10.1038/s41443-021-00422-x .
doi: 10.1038/s41443-021-00422-x
Lu L, Luo F, Wang X. Gonadal tumor risk in pediatric and adolescent phenotypic females with disorders of sex development and Y chromosomal constitution with different genetic etiologies. Front Pediatr. 2022;10:856128. https://doi.org/10.3389/fped.2022.856128 .
doi: 10.3389/fped.2022.856128
pubmed: 35935368
pmcid: 9353051
Mendonca BB, Domenice S, Arnhold IJ, Costa EM. 46,XY disorders of sex development (DSD). Clin Endocrinol (Oxf). 2009;70. https://doi.org/10.1111/j.1365-2265.2008.03392.x . :2:173 – 87.
Rey RA, Grinspon RP. Normal male sexual differentiation and aetiology of disorders of sex development. Best Pract Res Clin Endocrinol Metab. 2011;25:2221–38. https://doi.org/10.1016/j.beem.2010.08.013 .
doi: 10.1016/j.beem.2010.08.013
Ono M, Harley VR. Disorders of sex development: new genes, new concepts. Nat Rev Endocrinol. 2013;9:2:79–91. https://doi.org/10.1038/nrendo.2012.235 .
doi: 10.1038/nrendo.2012.235
pubmed: 23296159
Delot EC, Vilain E. Towards improved genetic diagnosis of human differences of sex development. Nat Rev Genet. 2021;22:9:588–602. https://doi.org/10.1038/s41576-021-00365-5 .
doi: 10.1038/s41576-021-00365-5
pubmed: 34083777
pmcid: 10598994
Ahmed SF, Bashamboo A, Lucas-Herald A, McElreavey K. Understanding the genetic aetiology in patients with XY DSD. Br Med Bull. 2013;106:67–89. https://doi.org/10.1093/bmb/ldt008 .
doi: 10.1093/bmb/ldt008
pubmed: 23529942
Luo X, Wang R, Sun Y, Qiu W, Lu D, Wang Y, et al. Deep intronic PAH variants explain missing heritability in Hyperphenylalaninemia. J Mol Diagn. 2023;25:5. https://doi.org/10.1016/j.jmoldx.2023.02.001 .
doi: 10.1016/j.jmoldx.2023.02.001
Chen S, Zhou Y, Chen Y, Gu J. Fastp: an ultra-fast all-in-one FASTQ preprocessor. Bioinformatics. 2018;34:i17884–90. https://doi.org/10.1093/bioinformatics/bty560 .
doi: 10.1093/bioinformatics/bty560
Li H, Durbin R. Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics. 2009;25:14:1754–60. https://doi.org/10.1093/bioinformatics/btp324 .
doi: 10.1093/bioinformatics/btp324
pubmed: 19451168
pmcid: 2705234
Li H, Handsaker B, Wysoker A, Fennell T, Ruan J, Homer N, et al. The sequence Alignment/Map format and SAMtools. Bioinformatics. 2009;25:16. https://doi.org/10.1093/bioinformatics/btp352 .
doi: 10.1093/bioinformatics/btp352
Van der Auwera GA, Carneiro MO, Hartl C, Poplin R, Del Angel G, Levy-Moonshine A, et al. From FastQ data to high confidence variant calls: the Genome Analysis Toolkit best practices pipeline. Curr Protoc Bioinf. 2013;43:11. https://doi.org/10.1002/0471250953.bi1110s43 .
doi: 10.1002/0471250953.bi1110s43
Wang K, Li M, Hakonarson H. ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data. Nucleic Acids Res. 2010;38:16e164. https://doi.org/10.1093/nar/gkq603 .
doi: 10.1093/nar/gkq603
Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med. 2015;17:5405–24. https://doi.org/10.1038/gim.2015.30 .
doi: 10.1038/gim.2015.30
Kopanos C, Tsiolkas V, Kouris A, Chapple CE, Albarca Aguilera M, Meyer R, et al. VarSome: the human genomic variant search engine. Bioinformatics. 2019;35:11. https://doi.org/10.1093/bioinformatics/bty897 .
doi: 10.1093/bioinformatics/bty897
Wang H, Zhang L, Wang N, Zhu H, Han B, Sun F, et al. Next-generation sequencing reveals genetic landscape in 46, XY disorders of sexual development patients with variable phenotypes. Hum Genet. 2018;137:3265–77. https://doi.org/10.1007/s00439-018-1879-y .
doi: 10.1007/s00439-018-1879-y
Yu BQ, Liu ZX, Gao YJ, Wang X, Mao JF, Nie M, et al. Prevalence of gene mutations in a Chinese 46,XY disorders of sex development cohort detected by targeted next-generation sequencing. Asian J Androl. 2021;23(1):69–73. https://doi.org/10.4103/aja.aja_36_20 .
doi: 10.4103/aja.aja_36_20
pubmed: 32985417
Zhang B, Song Y, Li W, Gong C. Variant analysis of the chromodomain helicase DNA-binding protein 7 in pediatric disorders of sex development. Pediatr Investig. 2019;3:131–8. https://doi.org/10.1002/ped4.12111 .
doi: 10.1002/ped4.12111
Alimussina M, Diver LA, McGowan R, Ahmed SF. Genetic testing of XY newborns with a suspected disorder of sex development. Curr Opin Pediatr. 2018;30:4. https://doi.org/10.1097/MOP.0000000000000644 .
doi: 10.1097/MOP.0000000000000644
Yatsenko SA, Witchel SF. Genetic approach to ambiguous genitalia and disorders of sex development: what clinicians need to know. Semin Perinatol. 2017;41:4. https://doi.org/10.1053/j.semperi.2017.03.016 .
doi: 10.1053/j.semperi.2017.03.016
Pleskacova J, Hersmus R, Oosterhuis JW, Setyawati BA, Faradz SM, Cools M, et al. Tumor risk in disorders of sex development. Sex Dev. 2010;4:4–5. https://doi.org/10.1159/000314536 .
doi: 10.1159/000314536
Sauna ZE, Kimchi-Sarfaty C. Understanding the contribution of synonymous mutations to human disease. Nat Rev Genet. 2011;12:10. https://doi.org/10.1038/nrg3051 .
doi: 10.1038/nrg3051
Batista RL, Mendonca BB. Integrative and Analytical Review of the 5-Alpha-reductase type 2 Deficiency Worldwide. Appl Clin Genet. 2020;13:83–96. https://doi.org/10.2147/TACG.S198178 .
doi: 10.2147/TACG.S198178
pubmed: 32346305
pmcid: 7167369
Han B, Cheng T, Zhu H, Yu J, Zhu WJ, Song HD, et al. Genetic analysis of 25 patients with 5alpha-Reductase Deficiency in Chinese Population. Biomed Res Int. 2020;2020:1789514. https://doi.org/10.1155/2020/1789514 .
doi: 10.1155/2020/1789514
pubmed: 32596280
pmcid: 7301183
Gui B, Song Y, Su Z, Luo FH, Chen L, Wang X, et al. New insights into 5alpha-reductase type 2 deficiency based on a multi-centre study: regional distribution and genotype-phenotype profiling of SRD5A2 in 190 Chinese patients. J Med Genet. 2019;56:10685–92. https://doi.org/10.1136/jmedgenet-2018-105915 .
doi: 10.1136/jmedgenet-2018-105915
Palui R, Ravichandran L, Kamalanathan S, Chapla A, Sahoo J, Narayanan N, et al. Clinical, hormonal, and genetic spectrum of 46 XY disorders of sexual development (DSD) patients. Indian J Pediatr. 2024. https://doi.org/10.1007/s12098-024-05144-8 .
doi: 10.1007/s12098-024-05144-8
pubmed: 38761274
Akcan N, Uyguner O, Bas F, Altunoglu U, Toksoy G, Karaman B, et al. Mutations in AR or SRD5A2 genes: clinical findings, endocrine pitfalls, and genetic features of children with 46,XY DSD. J Clin Res Pediatr Endocrinol. 2022;14:2153–71. https://doi.org/10.4274/jcrpe.galenos.2022.2021-9-19 .
doi: 10.4274/jcrpe.galenos.2022.2021-9-19
Hughes IA. Consequences of the Chicago DSD Consensus: a personal perspective. Horm Metab Res. 2015;47:5:394–400. https://doi.org/10.1055/s-0035-1545274 .
doi: 10.1055/s-0035-1545274
pubmed: 25750076
Mendonca BB, Inacio M, Costa EM, Arnhold IJ, Silva FA, Nicolau W, et al. Male pseudohermaphroditism due to steroid 5alpha-reductase 2 deficiency. Diagnosis, psychological evaluation, and management. Med (Baltim). 1996;75:2:64–76. https://doi.org/10.1097/00005792-199603000-00003 .
doi: 10.1097/00005792-199603000-00003
Davey RA, Grossmann M. Androgen receptor structure, function and Biology: from bench to Bedside. Clin Biochem Rev. 2016;37:1:3–15. https://www.ncbi.nlm.nih.gov/pubmed/27057074 .
pubmed: 27057074
pmcid: 4810760
Newmark JR, Hardy DO, Tonb DC, Carter BS, Epstein JI, Isaacs WB, et al. Androgen receptor gene mutations in human prostate cancer. Proc Natl Acad Sci U S A. 1992;89:14. https://doi.org/10.1073/pnas.89.14.6319 .
doi: 10.1073/pnas.89.14.6319
Lv SD, Wang HY, Yu XP, Zhai QL, Wu YB, Wei Q, et al. Integrative molecular characterization of Chinese prostate cancer specimens. Asian J Androl. 2020;22(2):162–8. https://doi.org/10.4103/aja.aja_36_19 .
doi: 10.4103/aja.aja_36_19
pubmed: 31134918
Torquato S, Pallavajjala A, Goldstein A, Toro PV, Silberstein JL, Lee J, et al. Genetic alterations detected in cell-free DNA are Associated with Enzalutamide and Abiraterone Resistance in Castration-resistant prostate Cancer. JCO Precis Oncol. 2019;3. https://doi.org/10.1200/PO.18.00227 .
Lanciotti L, Cofini M, Leonardi A, Bertozzi M, Penta L, Esposito S. Different clinical presentations and management in complete androgen insensitivity syndrome (CAIS). Int J Environ Res Public Health. 2019;16:7. https://doi.org/10.3390/ijerph16071268 .
doi: 10.3390/ijerph16071268
Yang J, Zhao S, Su J, Liu S, Wu Z, Ma W, et al. Comprehensive genomic profiling reveals prognostic signatures and insights into the molecular landscape of colorectal cancer. Front Oncol. 2023;13:1285508. https://doi.org/10.3389/fonc.2023.1285508 .
doi: 10.3389/fonc.2023.1285508
pubmed: 38023196
pmcid: 10680082
Bouvattier C, Mignot B, Lefevre H, Morel Y, Bougneres P. Impaired sexual activity in male adults with partial androgen insensitivity. J Clin Endocrinol Metab. 2006;91:9:3310–5. https://doi.org/10.1210/jc.2006-0218 .
doi: 10.1210/jc.2006-0218
pubmed: 16757528
Su L, Cheng J, Yin X, Liu G, Lu Z, Sheng H, et al. Clinical and molecular characteristics in 15 patients with androgen receptor gene mutations from South China. Andrologia. 2017;49:10. https://doi.org/10.1111/and.12763 .
doi: 10.1111/and.12763
Kalfa N, Philibert P, Werner R, Audran F, Bashamboo A, Lehors H, et al. Minor hypospadias: the tip of the iceberg of the partial androgen insensitivity syndrome. PLoS ONE. 2013;8:4e61824. https://doi.org/10.1371/journal.pone.0061824 .
doi: 10.1371/journal.pone.0061824
Ea V, Bergougnoux A, Philibert P, Servant-Fauconnet N, Faure A, Breaud J, et al. How far should we explore Hypospadias? Next-generation sequencing Applied to a large cohort of Hypospadiac patients. Eur Urol. 2021;79:4507–15. https://doi.org/10.1016/j.eururo.2020.12.036 .
doi: 10.1016/j.eururo.2020.12.036
Reddy NC, Majidi SP, Kong L, Nemera M, Ferguson CJ, Moore M, et al. CHARGE syndrome protein CHD7 regulates epigenomic activation of enhancers in granule cell precursors and gyrification of the cerebellum. Nat Commun. 2021;12:15702. https://doi.org/10.1038/s41467-021-25846-3 .
doi: 10.1038/s41467-021-25846-3
van Ravenswaaij-Arts C, Martin DM. New insights and advances in CHARGE syndrome: diagnosis, etiologies, treatments, and research discoveries. Am J Med Genet C Semin Med Genet. 2017;175:4:397–406. https://doi.org/10.1002/ajmg.c.31592 .
doi: 10.1002/ajmg.c.31592
pubmed: 29171162
pmcid: 6591023
Wang Y, Jiang W, Xia X. Clinical and molecular features of 40 Chinese patients with idiopathic hypogonadotropic hypogonadism. Transl Androl Urol. 2023;12:9. https://doi.org/10.21037/tau-23-225 .
doi: 10.21037/tau-23-225
pubmed: 36760870
Zhang W, Shi J, Zhang C, Jiang X, Wang J, Wang W, et al. Identification of gene variants in 130 Han Chinese patients with hypospadias by targeted next-generation sequencing. Mol Genet Genomic Med. 2019;7:8e827. https://doi.org/10.1002/mgg3.827 .
doi: 10.1002/mgg3.827
Janssen N, Bergman JE, Swertz MA, Tranebjaerg L, Lodahl M, Schoots J, et al. Mutation update on the CHD7 gene involved in CHARGE syndrome. Hum Mutat. 2012;33:8:1149–60. https://doi.org/10.1002/humu.22086 .
doi: 10.1002/humu.22086
pubmed: 22461308
Husu E, Hove HD, Farholt S, Bille M, Tranebjaerg L, Vogel I, et al. Phenotype in 18 Danish subjects with genetically verified CHARGE syndrome. Clin Genet. 2013;83:2. https://doi.org/10.1111/j.1399-0004.2012.01884.x .
doi: 10.1111/j.1399-0004.2012.01884.x
Bademci G, Cengiz FB, Foster Ii J, Duman D, Sennaroglu L, Diaz-Horta O, et al. Variations in multiple syndromic deafness genes mimic non-syndromic hearing loss. Sci Rep. 2016;6:31622. https://doi.org/10.1038/srep31622 .
doi: 10.1038/srep31622
pubmed: 27562378
pmcid: 4999867
Marcos S, Sarfati J, Leroy C, Fouveaut C, Parent P, Metz C, et al. The prevalence of CHD7 missense versus truncating mutations is higher in patients with Kallmann syndrome than in typical CHARGE patients. J Clin Endocrinol Metab. 2014;99:E102138–43. https://doi.org/10.1210/jc.2014-2110 .
doi: 10.1210/jc.2014-2110
Balasubramanian R, Choi JH, Francescatto L, Willer J, Horton ER, Asimacopoulos EP, et al. Functionally compromised CHD7 alleles in patients with isolated GnRH deficiency. Proc Natl Acad Sci U S A. 2014;111:50:17953–8. https://doi.org/10.1073/pnas.1417438111 .
doi: 10.1073/pnas.1417438111
pubmed: 25472840
pmcid: 4273325
Stamou MI, Georgopoulos NA. Kallmann syndrome: phenotype and genotype of hypogonadotropic hypogonadism. Metabolism. 2018;86:124–34. https://doi.org/10.1016/j.metabol.2017.10.012 .
doi: 10.1016/j.metabol.2017.10.012
pubmed: 29108899
Swee DS, Quinton R. Congenital Hypogonadotrophic Hypogonadism: Minipuberty and the case for neonatal diagnosis. Front Endocrinol (Lausanne). 2019;10:97. https://doi.org/10.3389/fendo.2019.00097 .
doi: 10.3389/fendo.2019.00097
pubmed: 30846970
Kim JH, Kang E, Heo SH, Kim GH, Jang JH, Cho EH, et al. Diagnostic yield of targeted gene panel sequencing to identify the genetic etiology of disorders of sex development. Mol Cell Endocrinol. 2017;444:19–25. https://doi.org/10.1016/j.mce.2017.01.037 .
doi: 10.1016/j.mce.2017.01.037
pubmed: 28130116
Ostrer H. Disorders of sex development (DSDs): an update. J Clin Endocrinol Metab. 2014;99:5:1503–9. https://doi.org/10.1210/jc.2013-3690 .
doi: 10.1210/jc.2013-3690
pubmed: 24758178
Eggers S, Sadedin S, van den Bergen JA, Robevska G, Ohnesorg T, Hewitt J, et al. Disorders of sex development: insights from targeted gene sequencing of a large international patient cohort. Genome Biol. 2016;17:1243. https://doi.org/10.1186/s13059-016-1105-y .
doi: 10.1186/s13059-016-1105-y
Zhao Z, Zhan Y, Chen W, Ma X, Sheng W, Huang G. Functional analysis of rare variants of GATA4 identified in Chinese patients with congenital heart defect. Genesis. 2019;57:11–2. https://doi.org/10.1002/dvg.23333 .
doi: 10.1002/dvg.23333
Deutsch GB, Zielonka EM, Coutandin D, Weber TA, Schafer B, Hannewald J, et al. DNA damage in oocytes induces a switch of the quality control factor TAp63alpha from dimer to tetramer. Cell. 2011;144:4566–76. https://doi.org/10.1016/j.cell.2011.01.013 .
doi: 10.1016/j.cell.2011.01.013
Kim DA, Suh EK. Defying DNA double-strand break-induced death during prophase I meiosis by temporal TAp63alpha phosphorylation regulation in developing mouse oocytes. Mol Cell Biol. 2014;34:8. https://doi.org/10.1128/MCB.01223-13 .
doi: 10.1128/MCB.01223-13
Turan S, Bastepe M. GNAS Spectrum of disorders. Curr Osteoporos Rep. 2015;13(3):146–58. https://doi.org/10.1007/s11914-015-0268-x .
doi: 10.1007/s11914-015-0268-x
pubmed: 25851935
pmcid: 4417430
Chen X, Meng Y, Tang M, Wang Y, Xie Y, Wan S, et al. A paternally inherited non-sense variant c.424G > T (p.G142*) in the first exon of XLalphas in an adult patient with hypophosphatemia and osteopetrosis. Clin Genet. 2020;97:5. https://doi.org/10.1111/cge.13734 .
doi: 10.1111/cge.13734
Richard N, Molin A, Coudray N, Rault-Guillaume P, Juppner H, Kottler ML. Paternal GNAS mutations lead to severe intrauterine growth retardation (IUGR) and provide evidence for a role of XLalphas in fetal development. J Clin Endocrinol Metab. 2013;98:E91549–56. https://doi.org/10.1210/jc.2013-1667 .
doi: 10.1210/jc.2013-1667
Mazen I, Abdel-Hamid M, Mekkawy M, Bignon-Topalovic J, Boudjenah R, El Gammal M, et al. Identification of NR5A1 mutations and possible digenic inheritance in 46,XY gonadal dysgenesis. Sex Dev. 2016;10:3147–51. https://doi.org/10.1159/000445983 .
doi: 10.1159/000445983
Sarfati J, Guiochon-Mantel A, Rondard P, Arnulf I, Garcia-Pinero A, Wolczynski S, et al. A comparative phenotypic study of Kallmann syndrome patients carrying monoallelic and biallelic mutations in the prokineticin 2 or prokineticin receptor 2 genes. J Clin Endocrinol Metab. 2010;95:2. https://doi.org/10.1210/jc.2009-0843 .
doi: 10.1210/jc.2009-0843
Wang Y, Qin M, Fan L, Gong C. Correlation Analysis of Genotypes and phenotypes in Chinese Male Pediatric patients with congenital hypogonadotropic hypogonadism. Front Endocrinol (Lausanne). 2022;13:846801. https://doi.org/10.3389/fendo.2022.846801 .
doi: 10.3389/fendo.2022.846801
pubmed: 35669683
Sykiotis GP, Plummer L, Hughes VA, Au M, Durrani S, Nayak-Young S, et al. Oligogenic basis of isolated gonadotropin-releasing hormone deficiency. Proc Natl Acad Sci U S A. 2010;107:34:15140–4. https://doi.org/10.1073/pnas.1009622107 .
doi: 10.1073/pnas.1009622107
pubmed: 20696889
pmcid: 2930591
Fluck CE, Audi L, Fernandez-Cancio M, Sauter KS, Martinez de LaPiscina I, Castano L, et al. Broad Phenotypes of Disorders/Differences of Sex Development in MAMLD1 patients through oligogenic disease. Front Genet. 2019;10:746. https://doi.org/10.3389/fgene.2019.00746 .
doi: 10.3389/fgene.2019.00746
pubmed: 31555317
pmcid: 6726737
YF Xu ea. New insights from unbiased panel and whole-exome sequencing in a large Chinese Cohort with Disorders of Sex Developmen. Eur Soc Endocrinol. 2019; https://doi.org/10.1530/EJE-19-0111. .
Xu Y, Wang Y, Li N, Yao R, Li G, Li J, et al. New insights from unbiased panel and whole-exome sequencing in a large Chinese cohort with disorders of sex development. Eur J Endocrinol. 2019;181:3:311 − 23; https://doi.org/10.1530/EJE-19-0111 .
Fan L, Song Y, Polak M, Li L, Ren X, Zhang B, et al. Clinical characteristics and genotype-phenotype correlations of 130 Chinese children in a high-homogeneity single-center cohort with 5alpha-reductase 2 deficiency. Mol Genet Genomic Med. 2020;8:10:e1431; https://doi.org/10.1002/mgg3.1431 .
Xie QG, Luo P, Xia K, Li ZQ, Xu Z, Su C, et al. 46,XY disorders of sex development: the use of NGS for prevalent variants. Hum Genet. 2022;141:12:1863-73; https://doi.org/10.1007/s00439-022-02465-6 .
Tang Y, Chen Y, Wang J, Zhang Q, Wang Y, Xu Y, et al. Clinical characteristics and genetic expansion of 46,XY disorders of sex development children in a Chinese prospective study. Endocr Connect. 2023;12:10; https://doi.org/10.1530/EC-23-0029 .
White S, Ohnesorg T, Notini A, Roeszler K, Hewitt J, Daggag H, et al. Copy number variation in patients with disorders of sex development due to 46,XY gonadal dysgenesis. PLoS One. 2011;6:3:e17793; https://doi.org/10.1371/journal.pone.0017793 .